Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

Radnor Capital Management LLC lifted its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,000 shares of the medical instruments supplier’s stock after purchasing an additional 3,398 shares during the period. Radnor Capital Management LLC’s holdings in West Pharmaceutical Services were worth $1,651,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. North Dakota State Investment Board acquired a new position in shares of West Pharmaceutical Services during the 4th quarter worth about $675,000. Elyxium Wealth LLC acquired a new position in shares of West Pharmaceutical Services during the 4th quarter worth about $25,000. Canada Post Corp Registered Pension Plan increased its stake in shares of West Pharmaceutical Services by 41.1% during the 4th quarter. Canada Post Corp Registered Pension Plan now owns 1,305 shares of the medical instruments supplier’s stock worth $359,000 after purchasing an additional 380 shares during the last quarter. DNB Asset Management AS increased its stake in shares of West Pharmaceutical Services by 7.2% during the 4th quarter. DNB Asset Management AS now owns 14,447 shares of the medical instruments supplier’s stock worth $3,975,000 after purchasing an additional 975 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of West Pharmaceutical Services by 377.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 16,398 shares of the medical instruments supplier’s stock worth $4,512,000 after purchasing an additional 12,963 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer owned 1,523 shares in the company, valued at $457,920.41. This represents a 37.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the transaction, the vice president owned 16,828 shares in the company, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Morgan Stanley set a $315.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, April 27th. UBS Group reiterated a “buy” rating and issued a $340.00 price target on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Barclays upped their price target on shares of West Pharmaceutical Services from $275.00 to $310.00 and gave the company an “equal weight” rating in a research note on Monday, April 27th. Evercore reiterated an “outperform” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $322.89.

West Pharmaceutical Services Stock Up 0.5%

Shares of WST opened at $304.31 on Tuesday. West Pharmaceutical Services, Inc. has a 52 week low of $203.74 and a 52 week high of $330.88. The firm has a market cap of $21.50 billion, a P/E ratio of 40.68, a price-to-earnings-growth ratio of 2.53 and a beta of 1.17. The firm’s 50-day simple moving average is $269.91 and its 200 day simple moving average is $265.43. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business had revenue of $844.90 million for the quarter, compared to analyst estimates of $779.68 million. During the same quarter in the prior year, the business earned $1.45 EPS. West Pharmaceutical Services’s quarterly revenue was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, analysts forecast that West Pharmaceutical Services, Inc. will post 8.61 earnings per share for the current year.

West Pharmaceutical Services declared that its Board of Directors has initiated a share buyback program on Tuesday, February 17th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 5.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.